StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Provectus Biopharmaceuticals's total assets was $1.47M at Jun 30, 2026. For fiscal 2025 it was $697.50K, down 30.7% from the year before. Over ten years it grew -28.7% a year on average. The highest annual figure on record is $26.18M in fiscal 2014.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$697.50K-30.7%
FY2024Dec 31, 2024$1.01M-30.5%
FY2023Dec 31, 2023$1.45M-28.9%
FY2022Dec 31, 2022$2.04M-42.0%
FY2021Dec 31, 2021$3.51M+496.3%
FY2020Dec 31, 2020$589.20K-60.1%
FY2019Dec 31, 2019$1.48M-25.7%
FY2018Dec 31, 2018$1.99M-42.1%
FY2017Dec 31, 2017$3.44M-38.8%
FY2016Dec 31, 2016$5.61M-72.5%
FY2015Dec 31, 2015$20.44M-21.9%
FY2014Dec 31, 2014$26.18M+30.9%
FY2013Dec 31, 2013$20.01M+222.5%
FY2012Dec 31, 2012$6.20M-53.5%
FY2011Dec 31, 2011$13.35M-7.3%
FY2010Dec 31, 2010$14.40M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.47M+104.0%
Q1 FY2026Mar 31, 2026$577.58K-13.3%
Q4 FY2025Dec 31, 2025$697.50K-30.7%
Q3 FY2025Sep 30, 2025$419.90K-47.6%
Q2 FY2025Jun 30, 2025$722.38K-15.7%
Q1 FY2025Mar 31, 2025$666.26K-38.3%
Q4 FY2024Dec 31, 2024$1.01M-30.5%
Q3 FY2024Sep 30, 2024$802.03K-52.5%
Q2 FY2024Jun 30, 2024$856.43K-49.2%
Q1 FY2024Mar 31, 2024$1.08M-37.3%
Q4 FY2023Dec 31, 2023$1.45M-28.9%
Q3 FY2023Sep 30, 2023$1.69M-17.6%
Q2 FY2023Jun 30, 2023$1.69M-31.0%
Q1 FY2023Mar 31, 2023$1.72M-37.6%
Q4 FY2022Dec 31, 2022$2.04M-42.0%
Q3 FY2022Sep 30, 2022$2.05M+241.6%
Q2 FY2022Jun 30, 2022$2.44M+424.0%
Q1 FY2022Mar 31, 2022$2.76M+257.2%
Q4 FY2021Dec 31, 2021$3.51M+496.3%
Q3 FY2021Sep 30, 2021$600.34K-55.4%
Q2 FY2021Jun 30, 2021$466.30K-74.6%
Q1 FY2021Mar 31, 2021$771.42K-5.9%
Q4 FY2020Dec 31, 2020$589.20K-60.1%
Q3 FY2020Sep 30, 2020$1.34M-14.0%
Q2 FY2020Jun 30, 2020$1.84M-32.4%
Q1 FY2020Mar 31, 2020$819.96K-77.8%
Q4 FY2019Dec 31, 2019$1.48M-25.7%
Q3 FY2019Sep 30, 2019$1.56M-35.4%
Q2 FY2019Jun 30, 2019$2.72M-22.9%
Q1 FY2019Mar 31, 2019$3.69M+20.8%
Q4 FY2018Dec 31, 2018$1.99M-42.1%
Q3 FY2018Sep 30, 2018$2.42M-37.1%
Q2 FY2018Jun 30, 2018$3.53M-28.5%
Q1 FY2018Mar 31, 2018$3.06M-32.2%
Q4 FY2017Dec 31, 2017$3.44M-38.8%
Q3 FY2017Sep 30, 2017$3.85M-63.9%
Q2 FY2017Jun 30, 2017$4.93M–
Q1 FY2017Mar 31, 2017$4.51M–
Q4 FY2016Dec 31, 2016$5.61M–
Q3 FY2016Sep 30, 2016$10.69M–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?